Quarterly Cashflow and Activities Report

Oct 30th, 2020

Starpharma today released its Appendix 4C – Quarterly Cashflow Report for the period ended 30 September 2020.

Completion of Placement and SPP raises $48.9M in total

Oct 29th, 2020

Starpharma today announced that it has completed its Share Purchase Plan (SPP), raising $3.9 million. The SPP was conducted in conjunction with Starpharma’s recent institutional placement (Placement), which together have raised a total of $48.9 million. The issue of 2.6 million new shares under the SPP will be at $1.50 per share, being equivalent to the Placement share price.

Starpharma receives $5.7M R&D tax incentive refund

Oct 21st, 2020

Starpharma today announced that it has received a $5.7M R&D tax incentive refund which relates to the costs of research and development during the 2020 Financial Year. The refund is in respect of eligible R&D activities across Starpharma’s portfolio, including for COVID-19, DEP^® and VivaGel^® programs.

Shareholder Update October 2020

Oct 20th, 2020

In this issue:

>> Starpharma is expediting the development of the SPL7013 COVID‑19 nasal spray

>> Rapid progress in the DEP^® irinotecan phase 2 & preparations underway for clinical combinations

>> DEP^® irinotecan in combination with immuno-oncology showed superior performance in colon cancer models

>> VivaGel^® BV launched in Central & Eastern Europe and Nordic region

>> Fleurstat BVgel gains expanded TGA approval to include prevention of recurrent Bacterial Vaginosis (BV) indication

>> VivaGel^® BV has now been approved in 40 countries with further submissions underway

>> Starpharma awarded $1 million MRFF funding for COVID-19 nasal spray

>> DEP^® docetaxel update & patient case study

>> DEP^® cabazitaxel update & patient case study

>> Multiple DEP^® products showcased at AACR 2020 Annual Meeting

>> New DEP^® partnership signed with Chase Sun for anti-infective program

>> AstraZeneca’s AZD0466 trial opens at MD Anderson Cancer Center

>> Starpharma creates slow release soluble DEP^® remdesivir

>> DEP^® partnering, including Antibody Drug Conjugates

>> DEP^® lutetium; impressive efficacy in human prostate cancer model

>> Outlook, Annual Report & ESG Report & recent news 

2GB’s Jim Wilson interviews Starpharma CEO Dr Jackie Fairley

Aug 26th, 2020

2GB radios Jim Wilson interviewed Starpharma CEO Dr Jackie Fairley to get an update on how Starpharma is fast-tracking a nasal spray designed to be used as a preventative measure in the fight against COVID-19.

To listen to the full interview click here.

ABC News features Starpharma on ‘The Kohler Report’

Aug 26th, 2020

Starpharma was featured on ABC’s  finance news segment ‘The Kohler Report’, where Alan Kohler highlighted that Starpharma shares had risen 23% following the Company’s update on its SPL7013-based antiviral nasal spray, which has shown to have potent antiviral activity against COVID-19. The update included that Starpharma has commenced confidential commercial discussions with related parties.

To watch the full report, click here.

Austarlian Manufacturing writes about Starpharma identifying a manufacturer of its antiviral nasal spray for COVID-19

Aug 26th, 2020

Starpharma was recently featured in an article by Australian Manufacturing, a leading publication and resource for the manufacturing and industrial sector in Australia. The article noted Starpharma had undertaken a pilot manufacture for its SPL7013 antiviral nasal spray, which has been tested and confirmed to have potent antiviral activity against SARS-CoV-2, the virus that causes COVID-19. The article also highlightsed SPL has identified a manufacturer and are currently compiling documentation in preparation for regulatory submission.

To read the full article click here.

The Age: Starpharma CEO Dr Jackie Fairley on Australia’s need to turn homegrown research into commercial products

Jul 3rd, 2020

The Age interviewed Starpharma CEO Dr Jackie Fairley about how the COVID-19 pandemic could be the much needed catalyst for the pharmaceutical industry to improve the way they convert important research into commercial products. Dr Fairley also covered Starpharma’s recent activities in response to the pandemic including, the development of a nasal spray product using the antiviral dendrimer, SPL7013.

To read the full interview click here.

Shareholder Update May 2020

May 14th, 2020

In this issue:

>> VivaGel^® BV launched in Asia

>> Fleurstat BVgel launched in NZ

>> DEP^® irinotecan phase 2 commences after positive phase 1 results 

>> SPL7013 against SARS-COV-2 (coronavirus)

>> Fleurstat BVgel ranks as #1 topical BV treatment

>> Okamoto adds 11 more Asian countries to  licence

>> US regulatory update

>> COVID-19: Starpharma’s operations continue with minimal disruption

>> DEP^® docetaxel, DEP^® cabazitaxel and DEP^® irinotecan 

>> DEP^® patient case studies

>> AstraZeneca’s DEP^® trial ongoing in the US & US$3 million milestone payment received

>> New DEP^® ADC programs

>> DEP^® pipeline targets multiple high-value areas

>> Other DEP^® programs

>> Outlook, recent news & events

Shareholder Update January 2020

Jan 30th, 2020

In this issue: 

>> VivaGel^® BV launched in the UK

>> AstraZeneca first DEP^® product enters the clinic; triggers US$3M milestone

>> DEP^® cabazitaxel trial moves into phase 2 on positive results

>> Fleurstat BVgel marketing campaign; New Zealand launch planned

>> Dual strategy to achieve approval of the NDA in the US

>> Okamoto joins forces with Japanese government for STI prevention campaign

>> VivaGel^® condom receives regulatory approval in Europe

>> DEP^® docetaxel & DEP^® cabazitaxel clinical trial case studies

>> DEP^® irinotecan phase 1/2 trial

>> New candidate - DEP^® gemcitabine

>> GMP DEP^® facility licence

>> DEP^® combinations add further value

>> Outlook, recent news & events